Prelude Therapeutics Incorporated generated $12.1M in revenue in fiscal year 2025. This represents an increase of 73.4% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Prelude Therapeutics Incorporated has filed alongside them.

Annual figures, oldest first. Point at a bar to read its period.

PRLD Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	$12.1M+73.4%	$7.0M	N/A	N/A	N/A	N/A	N/A

PRLD Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q
Revenue	$5.7M	$4.6M	N/A	$6.5M+116.7%	$0	$0	N/A	$3.0M	N/A	N/A	N/A	N/A

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Prelude Therapeutics Incorporated financials

• Every PRLD statement on one page
• PRLD Net Income
• PRLD EPS (Diluted)
• PRLD Free Cash Flow
• PRLD Debt & Cash
• PRLD Balance Sheet

Frequently Asked Questions

What was Prelude Therapeutics Incorporated's revenue in fiscal year 2025?

Prelude Therapeutics Incorporated generated $12.1M in revenue in fiscal year 2025.

How fast is Prelude Therapeutics Incorporated's revenue growing?

Prelude Therapeutics Incorporated (PRLD) revenue rose by 73.4% year over year, from $7.0M to $12.1M in fiscal year 2025.

What was Prelude Therapeutics Incorporated's revenue in the most recent quarter?

Prelude Therapeutics Incorporated (PRLD) reported $5.7M in revenue in Q2 2026.

What does revenue mean on a financial statement?

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Prelude Therapeutics Incorporated (PRLD) reported on that line in every period on record.